Skip to main content

Table 1 Patient clinical data

From: In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment

NO.

Diagnosis

DH(y)

Weight loss(kg)

HE

Blood Chemistry

ESR

FC

ID

UB

ARD

OBI

Survival

A

IPT

45

9/64 (14.06%)

N

LAHTA, HCRP

11.37 ± 6.23

4.45 ± 1.23

No

N

RFP, PZA

AHSC, NC

YES

B

CFPT

12

8/58 (13.79%)

N

NAHBA, HCRP

21.37 ± 8.23

6.45 ± 2.23

No

N

NO

AHSC, NC

YES

C

IPT

28

17/75 (22.67%)

N

LAHBA, HCRP

35.38 ± 12

6.06 ± 1.60

No

N

NO

AHSC, NC

YES

D

IPT

0

14/58 (24.13%)

N

NAHBA, HCRP

26.67 ± 2.52

5.64 ± 1.12

No

N

NO

AHSC, NC

YES

  1. DH(y) disease history (years), HE hematology, ESR erythrocyte sedimentation rate, FC fibrinogen concentration, ID immunodeficiency, UB urine biochemistry, ARD allergy reaction drugs, OBI other bacterial infection, IPT infiltrative pulmonary tuberculosis, CFPT chronic fibrocavenous pulmonary tuberculosis, LAHBA low alpha-hydroxybutyric acid, NAHBA normal alpha-hydroxybutyric acid, HCRP high C- reactive protein, AHSC α-hemolytic streptococcus, NC Neisser’s coccus, N normal